NO20041216L - Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt - Google Patents
Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvektInfo
- Publication number
- NO20041216L NO20041216L NO20041216A NO20041216A NO20041216L NO 20041216 L NO20041216 L NO 20041216L NO 20041216 A NO20041216 A NO 20041216A NO 20041216 A NO20041216 A NO 20041216A NO 20041216 L NO20041216 L NO 20041216L
- Authority
- NO
- Norway
- Prior art keywords
- obesity
- imidazole
- preparation
- treatment
- carboxamide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32447301P | 2001-09-24 | 2001-09-24 | |
PCT/US2002/030545 WO2003040107A1 (fr) | 2001-09-24 | 2002-09-24 | Preparation et utilisation de derives d'imidazole dans le traitement de l'obesite |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20041216L true NO20041216L (no) | 2004-05-05 |
Family
ID=23263739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20041216A NO20041216L (no) | 2001-09-24 | 2004-03-23 | Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt |
Country Status (25)
Country | Link |
---|---|
US (2) | US6960601B2 (fr) |
EP (1) | EP1432691A1 (fr) |
JP (1) | JP2005508384A (fr) |
KR (1) | KR20040040472A (fr) |
CN (2) | CN1865248A (fr) |
AR (1) | AR036608A1 (fr) |
BR (1) | BR0212986A (fr) |
CA (1) | CA2459745A1 (fr) |
CO (1) | CO5560560A2 (fr) |
EC (1) | ECSP045076A (fr) |
GT (1) | GT200200188A (fr) |
HN (1) | HN2002000266A (fr) |
HR (1) | HRP20040308A2 (fr) |
HU (1) | HUP0402376A2 (fr) |
IL (1) | IL160524A0 (fr) |
MA (1) | MA27684A1 (fr) |
MX (1) | MXPA04002037A (fr) |
NO (1) | NO20041216L (fr) |
NZ (1) | NZ531841A (fr) |
PE (1) | PE20030547A1 (fr) |
PL (1) | PL369326A1 (fr) |
RU (1) | RU2004112770A (fr) |
UY (1) | UY27450A1 (fr) |
WO (1) | WO2003040107A1 (fr) |
ZA (1) | ZA200403035B (fr) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US7109216B2 (en) | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
TWI231757B (en) * | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
JP3813152B2 (ja) | 2002-03-12 | 2006-08-23 | メルク エンド カムパニー インコーポレーテッド | 置換アミド類 |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
WO2004058727A1 (fr) * | 2002-12-20 | 2004-07-15 | Bayer Pharmaceuticals Corporation | 3,5-dihydro-4-h-imidazol-4-ones substitues utilises dans le traitement de l'obesite |
CN101012193A (zh) | 2003-01-02 | 2007-08-08 | 霍夫曼-拉罗奇有限公司 | 新cb 1受体反激动剂 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
EP1621537A4 (fr) * | 2003-04-21 | 2008-12-31 | Daiichi Seiyaku Co | Derive heterocyclique a cinq chainons |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
WO2005011654A2 (fr) | 2003-07-29 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Derives de pyridyle et utilisation de ceux-ci en tant qu'agents therapeutiques |
US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
US7662821B2 (en) | 2003-10-08 | 2010-02-16 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
ATE348609T1 (de) | 2003-10-08 | 2007-01-15 | Schering Ag | Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer |
US7638515B2 (en) | 2003-10-08 | 2009-12-29 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
AU2004283056A1 (en) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds |
CA2543239A1 (fr) | 2003-11-05 | 2005-06-02 | F. Hoffmann-La Roche Ag | Derives d'heteroaryle en tant qu'activateurs de ppar |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
WO2005049593A2 (fr) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | Promoteurs de l'apoptose contenant n-acylsulfonamide |
BRPI0507120A (pt) | 2004-01-28 | 2007-06-19 | Hoffmann La Roche | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização |
US7173044B2 (en) * | 2004-02-19 | 2007-02-06 | Solvay Pharmaceuticals B.V. | Imidazoline derivatives having CB1-antagonistic activity |
BRPI0508594A (pt) * | 2004-03-08 | 2007-08-21 | Wyeth Corp | moduladores de canal de ìon |
US20080242716A1 (en) * | 2004-03-08 | 2008-10-02 | Robert Zelle | Ion Channel Modulators |
US20070197513A1 (en) * | 2004-03-08 | 2007-08-23 | Robert Zelle | Ion channel modulators |
EP1734963A4 (fr) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Methode destinee a traiter des hommes presentant des troubles metaboliques et anthropometriques |
RU2377238C2 (ru) | 2004-04-03 | 2009-12-27 | Астразенека Аб | Производные имидазола, активные в отношении рецептора св1 |
US20080153859A1 (en) | 2004-04-05 | 2008-06-26 | Hartmut Rehwinkel | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
MXPA06012813A (es) | 2004-05-10 | 2007-01-26 | Hoffmann La Roche | Pirrol o imidazol amidas para tratar la obesidad. |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
US7524867B2 (en) | 2004-05-28 | 2009-04-28 | Solvay Pharmaceuticals, B.V. | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity |
TW200616969A (en) * | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
EP1807063A2 (fr) | 2004-10-25 | 2007-07-18 | Solvay Pharmaceuticals GmbH | Compositions pharmaceutiques comprenant un antagoniste au recepteur cannabinoide cb1 et un activateur de canaux potassique pour le traitement de l'obesite et pathologies associees |
ATE486067T1 (de) | 2004-11-09 | 2010-11-15 | Hoffmann La Roche | Dibenzosuberon-derivate |
WO2006060190A2 (fr) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Derives d'imidazole |
WO2006060199A2 (fr) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Derives d'imidazole utilises dans le traitement des dysfonctionnements sexuels |
AU2006203845A1 (en) * | 2005-01-10 | 2006-07-13 | Alexandros Makriyannis | Novel heteropyrrole analogs acting on cannabiniod receptors |
JP2008528700A (ja) * | 2005-02-03 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Pparモジュレーターとしての化合物および組成物 |
WO2006088798A2 (fr) * | 2005-02-14 | 2006-08-24 | Albert Einstein College Of Medicine Of Yeshiva University | Modulation de canaux potassiques sensibles a atp hypothalamiques |
US8937184B2 (en) | 2005-02-16 | 2015-01-20 | Abbvie B.V. | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators |
DE102005017316A1 (de) * | 2005-04-14 | 2006-10-19 | Schering Ag | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
TWI337608B (en) | 2005-05-12 | 2011-02-21 | Abbott Lab | Apoptosis promoters |
US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
CA2613517A1 (fr) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Modulateurs des lxr a base de pyrazoles |
AT502258B1 (de) * | 2005-07-22 | 2007-09-15 | Univ Wien | Cox-i-inhibitorverbindungen |
DE602006006712D1 (de) * | 2005-08-18 | 2009-06-18 | Hoffmann La Roche | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren |
GB0518819D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
GB0518817D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
US7829586B2 (en) | 2005-09-30 | 2010-11-09 | Banyu Pharmaceutical Co., Ltd. | Aryl-substituted nitrogen-containing heterocyclic compounds |
JP5076091B2 (ja) | 2005-11-28 | 2012-11-21 | マドリガル・ファーマシューティカルズ・インコーポレーテッド | ジアシルグリセロールアシルトランスフェラーゼ(dgat)のインヒビター |
EP1834948A1 (fr) | 2006-03-15 | 2007-09-19 | Bayer Schering Pharma Aktiengesellschaft | Derives de tetrahydronaphtalene , procedes pour leur production et leur utilisation en tant qu'anti-inflammatoires |
US7795265B2 (en) * | 2006-04-14 | 2010-09-14 | Merck Sharp & Dohme Corp. | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators |
WO2007120688A2 (fr) * | 2006-04-14 | 2007-10-25 | Merck & Co., Inc. | Imidazole 4-carboxamides substitués utilisés en tant que modulateurs des récepteurs de cholécystokinine-1 |
JP2009533449A (ja) | 2006-04-14 | 2009-09-17 | メルク エンド カムパニー インコーポレーテッド | コレシストキニン−1受容体モジュレーターとしての置換イミダゾール4−カルボキサミド類 |
AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
CA2676222A1 (fr) | 2007-01-26 | 2008-07-31 | Merck & Co., Inc. | Aminopyrimidines substituees en tant que modulateurs du recepteur de la cholecystokinine-1 |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CN101772513B (zh) | 2007-06-04 | 2013-11-13 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
GB2451629A (en) * | 2007-08-06 | 2009-02-11 | Univ Sheffield | 1-(Azolylcarbonyl)-2-(hydroxymethyl)pyrrolidine derivatives for use as catalysts for asymmetric reduction of imines & reductive amination of ketones |
EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
PT2959900T (pt) | 2008-06-16 | 2017-06-22 | Univ Tennessee Res Found | Composto para tratamento do cancro |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
AR072707A1 (es) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos |
JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
CN102271509A (zh) | 2008-10-31 | 2011-12-07 | 默沙东公司 | 用于抗糖尿病药的新型环苯并咪唑衍生物 |
EP2358200A4 (fr) | 2008-11-17 | 2012-05-16 | Merck Sharp & Dohme | Amines bicycliques substituées pour le traitement du diabète |
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
CR20160269A (es) * | 2008-12-05 | 2016-08-16 | Abbvie Inc | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento del cancer y enfermedades comunes |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
WO2010080864A1 (fr) * | 2009-01-12 | 2010-07-15 | Array Biopharma Inc. | Composés contenant de la pipéridine et leurs utilisations |
WO2011011506A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
WO2011011508A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés doxazépine benzofusionnés en tant quinhibiteurs de la coenzyme-stéaroyle a delta-9 désaturase |
ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
CN102883607B (zh) | 2010-03-01 | 2015-07-22 | Gtx公司 | 用于治疗癌的化合物 |
WO2011137024A1 (fr) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Nouveaux inhibiteurs de spiropipéridine prolylcarboxypeptidase |
US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
NZ603876A (en) | 2010-05-13 | 2015-02-27 | Amgen Inc | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
WO2011156246A1 (fr) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Nouveaux inhibiteurs de prolylcarboxypeptidase |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
BR122021002201A8 (pt) | 2011-02-25 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença |
WO2012120051A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation |
EP2683702B1 (fr) | 2011-03-08 | 2014-12-24 | Sanofi | Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683701B1 (fr) | 2011-03-08 | 2014-12-24 | Sanofi | Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
MX2015001500A (es) | 2012-08-02 | 2015-04-08 | Merck Sharp & Dohme | Compuestos antidiabeticos triciclicos. |
CA2898482A1 (fr) | 2013-02-22 | 2014-08-28 | Linda L. Brockunier | Composes bicycliques antidiabetiques |
WO2014139388A1 (fr) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
WO2014197720A2 (fr) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation |
WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
MX2016014890A (es) | 2014-06-06 | 2017-05-01 | Res Triangle Inst | Agonistas del receptor de apelina (apj) y usos de los mismos. |
PE20190258A1 (es) | 2015-12-09 | 2019-02-25 | Res Triangle Inst | Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos |
WO2017157735A1 (fr) * | 2016-03-15 | 2017-09-21 | Bayer Cropscience Aktiengesellschaft | Sulfonylamides substitués pour lutter contre les ravageurs |
WO2018071526A1 (fr) * | 2016-10-12 | 2018-04-19 | Research Triangle Institute | Agonistes du récepteur de l'apéline (apj) hétérocyclique et leurs utilisations |
TW201822637A (zh) * | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
JP2020500192A (ja) * | 2016-11-18 | 2020-01-09 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ジアシルグリセリドo−アシルトランスフェラーゼ2の阻害薬として有用なインドール誘導体 |
WO2018106518A1 (fr) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
CN114641467A (zh) | 2019-11-07 | 2022-06-17 | 拜耳公司 | 用于防治动物有害物的取代的磺酰胺 |
CA3125847A1 (fr) | 2020-07-27 | 2022-01-27 | Makscientific, Llc | Procede de fabrication de composes biologiquement actifs et d'intermediaires connexes |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE140966C (fr) | ||||
US5091405A (en) | 1987-01-05 | 1992-02-25 | E. I. Du Pont De Nemours And Company | Insecticidal pyrazolines |
DE3808071A1 (de) | 1988-03-11 | 1989-09-21 | Basf Ag | Verfahren zur herstellung von acylierten imidazolen |
US5164406A (en) | 1988-06-02 | 1992-11-17 | Bristol-Myers Squibb Co. | Method for enhancing transdermal penetration and compositions useful therein |
DE4015535A1 (de) | 1990-05-15 | 1991-11-21 | Basf Ag | Verfahren zur herstellung von n-substituierten imidazolen |
DE69322254T2 (de) | 1992-01-13 | 1999-04-29 | Smithkline Beecham Corp | Pyridyl-substituierte imidazole |
US5550147A (en) | 1992-02-05 | 1996-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5565577A (en) | 1992-09-23 | 1996-10-15 | Smithkline Beecham Corporation | Process for preparing 1-alkyaryl-2-alkyl-5-formylimidazole |
PT924201E (pt) * | 1993-11-30 | 2002-06-28 | Searle & Co | Pirazolil-benzeno-sulfonamidas triciclicas substituidas e a sua utilizacao como inibidores de ciclo-oxigenase ii |
US5616601A (en) | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5519143A (en) | 1994-09-19 | 1996-05-21 | The Du Pont Merck Pharmaceutical Company | Process for the isolation and purification of an imidazole stereoisomer from a mixture of stereoisomers by selective precipitation |
EP0946518A1 (fr) | 1996-12-16 | 1999-10-06 | Ontogen Corporation | Modulateurs de proteines possedant des unites de reconnaissance de la phosphotyrosine |
BR9813835A (pt) | 1997-12-22 | 2000-10-10 | Du Pont Pharm Co | Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica |
CA2373510A1 (fr) * | 1999-05-12 | 2000-11-23 | Ortho-Mcneil Pharmaceutical, Inc. | Carboxamides de pyrazole utiles pour le traitement de l'obesite et d'autres troubles |
US6492516B1 (en) | 1999-05-14 | 2002-12-10 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
PE20011010A1 (es) | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
JP4267920B2 (ja) | 2001-01-26 | 2009-05-27 | 中外製薬株式会社 | 代謝調節剤として有用なマロニル−CoA脱炭酸酵素阻害剤 |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
-
2002
- 2002-09-23 UY UY27450A patent/UY27450A1/es unknown
- 2002-09-23 PE PE2002000931A patent/PE20030547A1/es not_active Application Discontinuation
- 2002-09-23 AR ARP020103574A patent/AR036608A1/es unknown
- 2002-09-23 GT GT200200188A patent/GT200200188A/es unknown
- 2002-09-23 HN HN2002000266A patent/HN2002000266A/es unknown
- 2002-09-24 JP JP2003542153A patent/JP2005508384A/ja not_active Withdrawn
- 2002-09-24 IL IL16052402A patent/IL160524A0/xx unknown
- 2002-09-24 HU HU0402376A patent/HUP0402376A2/hu unknown
- 2002-09-24 US US10/255,049 patent/US6960601B2/en not_active Expired - Fee Related
- 2002-09-24 CA CA002459745A patent/CA2459745A1/fr not_active Abandoned
- 2002-09-24 NZ NZ531841A patent/NZ531841A/en unknown
- 2002-09-24 KR KR10-2004-7004228A patent/KR20040040472A/ko not_active Application Discontinuation
- 2002-09-24 CN CNA2006100915133A patent/CN1865248A/zh active Pending
- 2002-09-24 BR BR0212986-8A patent/BR0212986A/pt not_active IP Right Cessation
- 2002-09-24 EP EP02780365A patent/EP1432691A1/fr not_active Withdrawn
- 2002-09-24 RU RU2004112770/04A patent/RU2004112770A/ru not_active Application Discontinuation
- 2002-09-24 CN CNA028186931A patent/CN1599724A/zh active Pending
- 2002-09-24 WO PCT/US2002/030545 patent/WO2003040107A1/fr not_active Application Discontinuation
- 2002-09-24 MX MXPA04002037A patent/MXPA04002037A/es unknown
- 2002-09-24 PL PL02369326A patent/PL369326A1/xx not_active Application Discontinuation
-
2004
- 2004-03-19 CO CO04026619A patent/CO5560560A2/es not_active Application Discontinuation
- 2004-03-23 NO NO20041216A patent/NO20041216L/no not_active Application Discontinuation
- 2004-03-31 HR HR20040308A patent/HRP20040308A2/xx not_active Application Discontinuation
- 2004-04-21 ZA ZA200403035A patent/ZA200403035B/en unknown
- 2004-04-22 EC EC2004005076A patent/ECSP045076A/es unknown
- 2004-04-23 MA MA27653A patent/MA27684A1/fr unknown
-
2005
- 2005-05-20 US US11/133,751 patent/US20050256167A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2459745A1 (fr) | 2003-05-15 |
PL369326A1 (en) | 2005-04-18 |
NZ531841A (en) | 2005-09-30 |
WO2003040107A8 (fr) | 2004-07-29 |
CN1865248A (zh) | 2006-11-22 |
PE20030547A1 (es) | 2003-08-18 |
BR0212986A (pt) | 2004-08-17 |
EP1432691A1 (fr) | 2004-06-30 |
US6960601B2 (en) | 2005-11-01 |
ZA200403035B (en) | 2005-04-21 |
ECSP045076A (es) | 2004-05-28 |
US20040063691A1 (en) | 2004-04-01 |
RU2004112770A (ru) | 2005-10-10 |
HN2002000266A (es) | 2003-11-16 |
KR20040040472A (ko) | 2004-05-12 |
MA27684A1 (fr) | 2006-01-02 |
IL160524A0 (en) | 2004-07-25 |
CN1599724A (zh) | 2005-03-23 |
CO5560560A2 (es) | 2005-09-30 |
AR036608A1 (es) | 2004-09-22 |
GT200200188A (es) | 2003-06-25 |
WO2003040107A1 (fr) | 2003-05-15 |
UY27450A1 (es) | 2003-04-30 |
MXPA04002037A (es) | 2004-06-07 |
JP2005508384A (ja) | 2005-03-31 |
US20050256167A1 (en) | 2005-11-17 |
HRP20040308A2 (en) | 2006-08-31 |
HUP0402376A2 (hu) | 2005-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20041216L (no) | Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt | |
NO20013380L (no) | 2-aminobenzoksazinonderivater for behandling av fedme | |
NO20055832D0 (no) | Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme | |
HUP0302719A3 (en) | Substituted amine derivatives and their use for the treatment of angiogenesis | |
IS7079A (is) | Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni | |
NO20052894D0 (no) | 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte | |
NO20014379L (no) | Anvendelse av Xenon for behandling av Neurointoksikasjoner | |
NO20051493L (no) | Imidazolpyridiner og fremgangsmater for fremstilling og anvendelse av de samme | |
NO20013381D0 (no) | 2-oksybenzoksazinonderivater for behandling av fedme | |
NO20051503D0 (no) | Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme. | |
NO20042635L (no) | 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin | |
NO20015542L (no) | Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner | |
DK1513836T3 (da) | Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf | |
DK1417189T3 (da) | Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf | |
DK1590321T3 (da) | Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf | |
NO20041214L (no) | Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer | |
DK1202996T3 (da) | Titanforbindelser, fremstilling og anvendelse heraf | |
DK1556382T3 (da) | 3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf | |
IS2487B (is) | Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á | |
NO20033120L (no) | 2-arylimino-2,3-dihydrotiazolderivater, fremgangsmåter for fremstilling derav og terapeutisk anvendelse derav | |
NO20034172D0 (no) | Bisykliske guanidinderivater og terapeutiske anvendelser derav | |
DE60216321D1 (de) | 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazinoä4,5-büindol-1-karboxamid-derivate, ihre herstellung und therapeutische verwendung | |
NO20033965L (no) | Caloporosidderivater, fremgangsmåte for deres fremstilling og deres anvendelse | |
NO20033697L (no) | Substituerte propan-1,3-diamin-derivater og den farmasöytiske anvendelse derav | |
NO20040935L (no) | Plaster for behandling av dysfunksjoner og forstyrrelser i negler. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |